2023
Imaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original ResearchPreliminary dosimetric comparison between fixed and rotating source stereotactic radiosurgery systems
Draeger E, Chen Z, Hansen J, Chiang V, Tien C. Preliminary dosimetric comparison between fixed and rotating source stereotactic radiosurgery systems. Journal Of Applied Clinical Medical Physics 2023, 24: e13907. PMID: 36660774, PMCID: PMC10161057, DOI: 10.1002/acm2.13907.Peer-Reviewed Original ResearchConceptsConformity indexRadiation Therapy Oncology Group conformity indexGK plansSuperior conformity indexNon-metastatic casesPaddick conformity indexDosimetric plan qualityGK patientsBrain metastasesRadiosurgery systemTrigeminal neuralgiaPrescription dosesGamma Knife systemMetastatic casesArteriovenous malformationsPituitary adenomasConformality indexLarge cohortDosimetric comparisonStereotactic radiosurgery systemGK IconPatientsCohortTreatment timeDosimetric results
2022
NIMG-02. PACS-INTEGRATED AUTO-SEGMENTATION WORKFLOW FOR BRAIN METASTASES USING NNU-NET
Jekel L, Bousabarah K, Lin M, Merkaj S, Kaur M, Avesta A, Aneja S, Omuro A, Chiang V, Scheffler B, Aboian M. NIMG-02. PACS-INTEGRATED AUTO-SEGMENTATION WORKFLOW FOR BRAIN METASTASES USING NNU-NET. Neuro-Oncology 2022, 24: vii162-vii162. PMCID: PMC9661012, DOI: 10.1093/neuonc/noac209.622.Peer-Reviewed Original ResearchNIMG-07. APPLYING A GLIOMA-TRAINED DEEP LEARNING AUTO-SEGMENTATION TOOL ON BM PRE- AND POST-RADIOSURGERY
Kaur M, Varghese S, Jekel L, Tillmanns N, Merkaj S, Bousabarah K, Lin M, Bhawnani J, Chiang V, Aboian M. NIMG-07. APPLYING A GLIOMA-TRAINED DEEP LEARNING AUTO-SEGMENTATION TOOL ON BM PRE- AND POST-RADIOSURGERY. Neuro-Oncology 2022, 24: vii162-vii163. PMCID: PMC9660643, DOI: 10.1093/neuonc/noac209.626.Peer-Reviewed Original ResearchStereotactic radiosurgeryPosttreatment lesionsBoard-certified neuroradiologistsRoutine clinical useWhole tumorTumor coreMulticentric lesionsTreatment responsePeritumoral edemaBM preLesionsClinical useVolumetric segmentationEdemaPatientsT2w FLAIRTherapy planningTumorsDedicated trainingLesion detectionBM dataVolumetric measurementsBMMRIPreHistological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases
Fomchenko EI, Leelatian N, Darbinyan A, Huttner AJ, Chiang VL. Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases. Journal Of Neurosurgery Case Lessons 2022, 4: case21373. PMID: 35855352, PMCID: PMC9257400, DOI: 10.3171/case21373.Peer-Reviewed Original ResearchLaser interstitial thermal therapyRadiation necrosisInterstitial thermal therapyBrain metastasesAssociated cerebral edemaStage IV diseaseUse of immunotherapyPredictors of responseOngoing immunotherapySurgical decompressionCerebral edemaPerilesional edemaSurgical approachClinical historyLung cancerNeurological compromiseGood patientHistological changesStereotactic radiosurgeryPatientsEarly reductionSized lesionsImmunotherapyTherapyThermal therapyBrain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
Aizer AA, Lamba N, Ahluwalia MS, Aldape K, Boire A, Brastianos PK, Brown PD, Camidge DR, Chiang VL, Davies MA, Hu LS, Huang RY, Kaufmann T, Kumthekar P, Lam K, Lee EQ, Lin NU, Mehta M, Parsons M, Reardon DA, Sheehan J, Soffietti R, Tawbi H, Weller M, Wen PY. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology 2022, 24: 1613-1646. PMID: 35762249, PMCID: PMC9527527, DOI: 10.1093/neuonc/noac118.Peer-Reviewed Original ResearchConceptsBrain metastasesConsensus reviewAdvanced solid malignanciesManagement of patientsOncologic careSimilar incidenceConsensus guidelinesSolid malignanciesDedicated trialsNeuro-oncologyMetastasisCurrent managementPatientsCareFurther explorationMalignancyReviewGroup discussionsManagementIncidenceTrials513 Surveilling Cerebrospinal Fluid Protein Biomarkers in Brain Metastasis
Cheok S, Arnal-Estape A, Wei W, Nguyen D, Chiang V. 513 Surveilling Cerebrospinal Fluid Protein Biomarkers in Brain Metastasis. Neurosurgery 2022, 68: 129-129. DOI: 10.1227/neu.0000000000001880_513.Peer-Reviewed Original ResearchBrain metastasesCerebrospinal fluidIntraparenchymal diseaseCentral nervous system pathologyCerebrospinal fluid (CSF) protein biomarkersIntraparenchymal brain metastasesManagement of patientsNormal pressure hydrocephalusNervous system pathologyCurrent diagnostic standardNon-malignant samplesWarrants further explorationCSF profilePressure hydrocephalusRadiation necrosisLung cancerSimilar pathogenesisBrain parenchymaInflammatory diseasesIntracranial diseaseBreast cancerClinical dataCSF leakTreatment responsePatientsReal-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery
Petersen G, Bousabarah K, Verma T, von Reppert M, Jekel L, Gordem A, Jang B, Merkaj S, Fadel S, Owens R, Omuro A, Chiang V, Ikuta I, Lin M, Aboian MS. Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery. Neuro-Oncology Advances 2022, 4: vdac116. PMID: 36043121, PMCID: PMC9412827, DOI: 10.1093/noajnl/vdac116.Peer-Reviewed Original ResearchGamma KnifeTreatment responseBrain metastasis patientsFurther treatment planningNumber of lesionsMean followBrain metastasesMetastasis patientsMultiple lesionsDiagnostic followSingle patientStereotactic radiosurgeryPatientsLesionsIndividual lesionsPrevalenceAccurate surveillanceHeterogenous responseTreatment planningTreatmentFollowRadiosurgerySize assessmentComprehensive assessmentResponse
2021
Adverse radiation effects in volume-staged radiosurgery for large arteriovenous malformations: a multiinstitutional study.
Seymour ZA, Chan JW, McDermott MW, Grills I, Ye H, Kano H, Lehocky CA, Jacobs RC, Lunsford LD, Chytka T, Liščák R, Lee CC, Yang HC, Ding D, Sheehan JP, Feliciano CE, Rodriguez-Mercado R, Chiang VL, Hess JA, Sommaruga S, McShane B, Lee JYK, Vasas LT, Kaufmann AM, Sneed PK. Adverse radiation effects in volume-staged radiosurgery for large arteriovenous malformations: a multiinstitutional study. Journal Of Neurosurgery 2021, 136: 503-511. PMID: 34450589, DOI: 10.3171/2020.12.jns201866.Peer-Reviewed Original ResearchConceptsAdverse radiation effectsLarge arteriovenous malformationsArteriovenous malformationsVS-SRSLobe involvementSymptomatic adverse radiation effectsVolume-staged stereotactic radiosurgeryMedian margin doseOptimal treatment paradigmAVM nidus volumeTemporal lobe involvementVolume-staged radiosurgeryParietal lobe involvementMultiinstitutional cohortRadiosurgical centersMargin doseMedian ageRetrospective reviewEntire nidusMaximal linear dimensionMultiinstitutional studyNidus volumeTreatment paradigmStereotactic radiosurgeryPatientsSURG-02. Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (SRS) as a treatment strategy for brain metastasis that recurred locally after initial radiosurgery (BMRS): a collaborative institutional experience
Pena-Pino I, Ma J, Hori Y, Fomchenko E, Dusenbery K, Reynolds M, Wilke C, Yuan J, Barnett G, Chiang V, Mohammadi A, Chen C. SURG-02. Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (SRS) as a treatment strategy for brain metastasis that recurred locally after initial radiosurgery (BMRS): a collaborative institutional experience. Neuro-Oncology Advances 2021, 3: iii23-iii23. PMCID: PMC8351296, DOI: 10.1093/noajnl/vdab071.095.Peer-Reviewed Original ResearchStereotactic laser ablationStereotactic radiosurgeryOverall survivalTreatment strategiesLocal controlDays of SRSSymptomatic radiation necrosisMedian overall survivalSystemic disease progressionRepeat stereotactic radiosurgeryIndependent clinical trialsInitial radiosurgerySteroid therapyBrain metastasesClinical outcomesRadiation necrosisFavorable outcomeClinical trialsDisease progressionFLAIR volumeInstitutional experiencePatientsCE volumeRadiosurgeryLocal failureComparison of radiomic feature aggregation methods for patients with multiple tumors
Chang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of radiomic feature aggregation methods for patients with multiple tumors. Scientific Reports 2021, 11: 9758. PMID: 33963236, PMCID: PMC8105371, DOI: 10.1038/s41598-021-89114-6.Peer-Reviewed Original ResearchConceptsCox proportional hazards modelCox proportional hazardsProportional hazards modelBrain metastasesRadiomic featuresHazards modelProportional hazardsStandard Cox proportional hazards modelMultifocal brain metastasesMultiple brain metastasesNumber of patientsPatient-level outcomesHigher concordance indexRadiomic feature analysisRandom survival forest modelSurvival modelsDifferent tumor volumesMultifocal tumorsCancer outcomesMultiple tumorsMetastatic cancerConcordance indexTumor volumePatientsTumor typesTumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF
Cheok SK, Narayan A, Arnal-Estape A, Gettinger S, Goldberg SB, Kluger HM, Nguyen D, Patel A, Chiang V. Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF. JCO Precision Oncology 2021, 5: 163-172. PMID: 34250381, PMCID: PMC8232069, DOI: 10.1200/po.20.00292.Peer-Reviewed Original ResearchConceptsIntraparenchymal brain metastasesBrain metastasesCell-free DNAExtracranial tumorsBrain metastasis tissuesProgressive brain metastasesThird of patientsNormal pressure hydrocephalusTumor DNA mutationsPrimary cancer typeAnalysis of CSFSamples of CSFLeptomeningeal diseaseEffective surrogate markerBrain biopsyPressure hydrocephalusLumbar punctureSurrogate markerCancer-associated genesMetastasis tissuesPatientsMetastasisDiscordant responsesRenal cellsGenomic profiling
2020
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto WA, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, An Y, Chiang V, Nakano T, Aoyama H, Mehta MP. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal Of Clinical Oncology 2020, 38: 3773-3784. PMID: 32931399, PMCID: PMC7655019, DOI: 10.1200/jco.20.01255.Peer-Reviewed Original ResearchConceptsGraded Prognostic AssessmentDiagnosis-Specific Graded Prognostic AssessmentBrain metastasesPrognostic factorsClinical trialsPrognostic assessmentLarge contemporary cohortSignificant prognostic factorsEnrollment of patientsNew prognostic factorsMulti-institutional databaseMedian survivalMultivariable analysisContemporary cohortWorse prognosisCell lungIndividualize treatmentTreatment choicePoor survivalRenal cancerPatientsPromising treatmentExpansion of eligibilityMetastasisPrimary siteExecutive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases
Milano MT, Chiang VLS, Soltys SG, Wang TJC, Lo SS, Brackett A, Nagpal S, Chao S, Garg AK, Jabbari S, Halasz LM, Gephart MH, Knisely JPS, Sahgal A, Chang EL. Executive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases. Neuro-Oncology 2020, 22: 1728-1741. PMID: 32780818, PMCID: PMC7746939, DOI: 10.1093/neuonc/noaa192.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyAsymptomatic brain metastasesGood performance statusBrain metastasesMultiple brain metastasesAppropriate use criteriaStereotactic radiosurgeryPerformance statusTreatment optionsAmerican Radium Society Appropriate Use CriteriaHippocampal Sparing-Whole Brain RadiotherapySystematic reviewConventional whole brain radiotherapySingle-fraction stereotactic radiosurgeryProgressive extracranial diseasePoor performance statusAppropriate treatment optionsQuality of evidenceBrainstem metastasesExtracranial diseaseConsensus guidelinesOptimal treatmentSystemic optionsNeurocognitive outcomesPatientsLaser interstitial thermal therapy (LITT) vs. bevacizumab for radiation necrosis in previously irradiated brain metastases
Sujijantarat N, Hong CS, Owusu KA, Elsamadicy AA, Antonios JP, Koo AB, Baehring JM, Chiang VL. Laser interstitial thermal therapy (LITT) vs. bevacizumab for radiation necrosis in previously irradiated brain metastases. Journal Of Neuro-Oncology 2020, 148: 641-649. PMID: 32602021, DOI: 10.1007/s11060-020-03570-0.Peer-Reviewed Original ResearchConceptsLaser interstitial thermal therapyLonger overall survivalRadiation necrosisInterstitial thermal therapyBrain metastasesOverall survivalMedian volume decreaseMedian volume increaseBrain metastasis patientsPre-treatment patient characteristicsRetrospective chart reviewResultsTwenty-five patientsPre-treatment factorsBevacizumab patientsChart reviewMetastasis patientsLocal recurrencePatient characteristicsTreatment optionsTreatment responseBevacizumabPatientsLesional volumeThermal therapyStatistical significance
2019
Complications associated with immunotherapy for brain metastases.
Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/wco.0000000000000756.Peer-Reviewed Original ResearchConceptsBrain metastasesNeurologic toxicityImmune therapyPhase 2 clinical trialCheckpoint inhibitor therapyImmune checkpoint inhibitorsMultiple phase 2 clinical trialsTreatment-related morbidityBrain metastatic diseaseSymptomatic edemaCheckpoint inhibitorsAdverse eventsDurable responsesMedian survivalMetastatic diseaseInhibitor therapyMore patientsIntracranial activityPatient groupRadiation necrosisClinical trialsTherapy trialsMultidisciplinary teamMetastasisPatientsA Proposed Grading Scale for Predicting Outcomes After Stereotactic Radiosurgery for Dural Arteriovenous Fistulas
Mohammed N, Hung YC, Chen CJ, Xu Z, Schlesinger D, Kano H, Chiang V, Hess J, Lee J, Mathieu D, Kaufmann AM, Grills IS, Cifarelli CP, Vargo JA, Chytka T, Janouskova L, Feliciano CE, Mercado RR, Lunsford LD, Sheehan JP. A Proposed Grading Scale for Predicting Outcomes After Stereotactic Radiosurgery for Dural Arteriovenous Fistulas. Neurosurgery 2019, 87: 247-255. PMID: 31584074, PMCID: PMC7528658, DOI: 10.1093/neuros/nyz401.Peer-Reviewed Original ResearchConceptsDural arteriovenous fistulaCranial dural arteriovenous fistulasCortical venous refluxFavorable outcomeStereotactic radiosurgeryGrading systemIntracerebral hemorrhageArteriovenous fistulaScoring systemGrading scaleKaplan-Meier analysisPrior intracerebral hemorrhageClass II patientsLogistic regression analysisPractical grading systemDAVF obliterationVenous refluxII patientsClinical parametersSinus locationPredicting OutcomeSystematic reviewClass IIIPatientsROC analysisFrequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors
Qian JM, Yu JB, Mahajan A, Goldberg SB, Kluger HM, Chiang VLS. Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: 1113-1118. PMID: 31479702, DOI: 10.1016/j.ijrobp.2019.08.053.Peer-Reviewed Original ResearchConceptsBrain metastasesLocal therapyNeurologic safetyMelanoma patientsProspective phase 2 trialProgressive brain metastasesSerial brain imagingMelanoma brain metastasesPD-1 inhibitorsPhase 2 trialRapid disease progressionManagement of patientsNeurologic symptomsMultidisciplinary careTrial enrollmentCystic changesClinical trialsDisease progressionPatientsLesion sizeMetastasisMultidisciplinary teamTumor growthTherapyClinical decisionRADI-34. USE OF LOW-DOSE STEREOTACTIC RADIOSURGERY FOR ADVANCED BRAIN METASTASES
Yang D, Yu J, Chiang V. RADI-34. USE OF LOW-DOSE STEREOTACTIC RADIOSURGERY FOR ADVANCED BRAIN METASTASES. Neuro-Oncology Advances 2019, 1: i28-i28. PMCID: PMC7213353, DOI: 10.1093/noajnl/vdz014.126.Peer-Reviewed Original ResearchGamma Knife stereotactic radiosurgeryBrain metastasesStereotactic radiosurgeryOverall survivalDisease progressionTime to disease progressionBRAF V600E tumorsMutation-targeted therapiesMedian overall survivalMetastatic melanoma patientsTreat brain metastasesPoor performance statusTumor controlMelanoma patientsSystemic therapyAdvanced diseasePerformance statusRe-treatmentTesticular cancerComposite endpointMetastasisSystemic agentsStudy exitImmunotherapyPatientsMLTI-06. BEVACIZUMAB VERSUS SURGICAL INTERVENTION FOR RADIATION NECROSIS IN PREVIOUSLY IRRADIATED BRAIN METASTASES
Hong C, Sujijantarat N, Chiang V. MLTI-06. BEVACIZUMAB VERSUS SURGICAL INTERVENTION FOR RADIATION NECROSIS IN PREVIOUSLY IRRADIATED BRAIN METASTASES. Neuro-Oncology Advances 2019, 1: i15-i15. PMCID: PMC7213266, DOI: 10.1093/noajnl/vdz014.065.Peer-Reviewed Original ResearchProgression-free survivalLaser interstitial thermal ablationBrain metastasesRadiation necrosisOverall survivalSurgical managementSurgical interventionSingle-institution chart reviewTime of interventionInterstitial thermal ablationBevacizumab cohortGood KPSLower KPSBevacizumab therapySurgery cohortChart reviewMedical managementTrue efficacyBevacizumabComparative outcomesPatientsLesionsComparison groupThermal ablationIntervention